Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
In Phase 3 TRIUMPH-1 (May 21, 2026), the 12 mg arm averaged 28.3% weight loss at 80 weeks, and a higher-BMI subgroup reached 30.3% at 104 weeks
Among these agents, semaglutide and liraglutide have consistently shown the strongest cardiovascular benefit, with semaglutide showing additional promise in patients with obesity and HFpEF
J Obes Metab syndrome (2021) 30(1):129
If your day-to-day eating patterns include large portions, frequent snacking, or liquid calories (sodas, alcohol, high-calorie coffee drinks), weight gain can occur despite active GLP-1 therapy
US$ 27.68
US$ 28.64
US$ 25.32
US$ 28.55
US$ 20.19
